Beverly Corporation Announces Anti-Cancer Drug at Annual Meeting

Beverly-based Cellceutix Corporation, biopharmaceutical company focused on cancer-related medicines, announced the poster for a new anti-cancer drug called Kevetrin, at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago recently, according an article in Market Watch. 

"The poster summarizes information from the ongoing Phase I trial being conducted at Harvard Cancer Centers, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Research is characterizing the pharmacokinetic profile of Kevetrin, along with evaluating preliminary evidence of anti-tumor activity and potential biomarkers of tumor response to Kevetrin by activation of p21."

Read more on Market Watch.com.